Privately-held US biotech Pandion Therapeutics and Japanese drugmaker Astellas (TYO: 4503) have announced a collaboration with a potential value of $795 million.
The agreement is for the research and development, and commercialization, of locally-acting bispecific antibodies for autoimmune diseases of the pancreas.
Pandion’s modular biologics and functional immunology expertise will be combined with Astellas' advanced therapeutics development and global commercialization capabilities for the treatment of autoimmune diseases.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze